an-najah 2 nd medical international conference
DESCRIPTION
An-Najah 2 nd Medical International Conference. “ Evidence based advances in women healthcare” 8-10/10/2009 Nablus- Palestine. Rubella immune status of Palestinian women. study of more than 870 ladies tested for Rubella IgG in the period 2002 and 2009. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/1.jpg)
An-Najah 2nd Medical International Conference
“Evidence based advances in women healthcare”
8-10/10/2009
Nablus- Palestine
![Page 2: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/2.jpg)
Rubella immune status of Palestinian women.
study of more than 870 ladies tested for Rubella IgG in the period 2002
and 2009
![Page 3: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/3.jpg)
Dr. Bashar Adnan Karmi Medicare-MediPal laboratories
MD, MSCClinical Pathologist
Immunologist/Microbiologist
![Page 4: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/4.jpg)
History
• The name rubella is derived from Latin, • meaning “little red” • Rubella was initially considered to be a variant
of measles or scarlet fever and was called “third disease.”
• In1814 Rubella was first described as separate disease in the German medical literature, hence the common name “German measles.”
![Page 5: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/5.jpg)
About rubella virus
• First isolated in 1962 by Parkman and Weller.• Classified as a toga virus, genus Rubivirus.• Most closely related to group A arboviruses,• It is an enveloped RNA virus, with a single
antigenic type that does not cross-react with other members of the toga virus group.
![Page 6: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/6.jpg)
Following a widespread epidemic of rubella infection in 1940
•Norman Gregg, Australian ophthalmologist, reported in 1941 the occurrence of congenital cataracts among 78 infants born following maternal rubella infection in early
pregnancy .
![Page 7: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/7.jpg)
This was the first reported recognition of congenital rubella syndrome (CRS)
![Page 8: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/8.jpg)
Maintenance of long-term antibody responses
• Is critical for protective immunity.
![Page 9: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/9.jpg)
About rubella vaccine
![Page 10: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/10.jpg)
About rubella vaccine
![Page 11: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/11.jpg)
About the vaccine
•The single component live attenuated vaccines of measles, mumps,
•and rubella have been licensed in the USA
•since the 1960s•Combined live attenuated measles, mumps
and rubella (MMR) vaccine was introduced•in the United States in the 1970s
![Page 12: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/12.jpg)
In total,
• over 90 countries around the world use MMR including our Palestine.
![Page 13: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/13.jpg)
The RA 27/3 strain is used most often because
•1 )it gives consistent immunogenicity
2 )has low rate of side effects.
The role of MMR in reducing the incidence of these three
diseases is agreed upon .
![Page 14: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/14.jpg)
The vaccine used in Palestine
• Is TRIMOVAX from Sanofi Pasteur. • Contains WHO approved Wistar RA 27/3M
strain cultivated in human diploid cells.• Each dose contains at least 1000 Cell Culture
Infectious Dose 50% (CCID).
![Page 15: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/15.jpg)
Currently according to MoH
• MMR is given in two dosages at age of 12 and 18 months.
• A third boosting dose is given to girls in 6th class.
• The coverage is nearly 100%• Since 1995 no registered CRS in Palestine.
![Page 16: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/16.jpg)
As we have no data regarding theimmune status for rubella, the aim of our
Cohort retrospective study
To assess 1) the % of rubella susceptible of age bearing
women in Palestinian community.•2 )efficiency of used vaccine vaccination
program.
•3 )subsequently the need for including rubella test as a routine test for pregnant ladies in their first pregnancies.
![Page 17: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/17.jpg)
Samples
• Samples were obtained from ladies attending Medicare MediPal laboratories in Ramallah, Nablus, Hebron, Jericho and Al Eizaria cities.
• Usually this was part of their pregnancy follow up.
• Serum samples was taken for rubella IgG and other ordered tests.
• Tests were done the same day or the day after.
![Page 18: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/18.jpg)
Method used
The method used in• Medicare- Medipal
• is the Abbott FDA approved AxSYM method which uses the Micro-particle Enzyme Immunoassay (MEIA) for qualitative and quantitative measurement of IgG antibodies to rubella virus in human serum or plasma.
![Page 19: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/19.jpg)
Hemagglutination Inhibition (HIA)
• Is often referred as the reference method.• Since 1980, rubella virus IgG assays have been
calibrated against the same WHO international standard rubella virus serum (second St. preparation) and test results reported in IU/ml.
![Page 20: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/20.jpg)
Results
• According to Abbott manufacturers, the presence of at least 10 International Units of antibody/ ml of sample is indicative of post exposure to rubella virus.
• Antibody levels below 10 IU/ml may be insufficient to provide protection from clinical illness.
![Page 21: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/21.jpg)
Initial Relative Sensitivity
• MEIA method used in AxSYM Abbott showed 99.5% (1082/1088) sensitivity
• The 95% CI 98.8%-99.8%
![Page 22: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/22.jpg)
Initial Relative Specificity
• MEIA method used in AxSYM Abbott showed 90.8% (316/348) specificity
• The 95% CI 87.3%-93.6%
![Page 23: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/23.jpg)
Number of tested subjects2002-2009
YearNumber tested200222
200319
200444
200578
200657
200792
2008287
2009277
TOTAL876
![Page 24: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/24.jpg)
Immunity status of tested subjects
![Page 25: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/25.jpg)
WHO Literature accepts
• Approximately 5% of vaccenees Not responding to vaccination ( negative sero-conversion) and will develop No ANTIBODIES to Rubella virus.
• This is due to:• 1) concurrent infection or to a• 2) low level of pre-existing antibodies.
![Page 26: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/26.jpg)
Age distribution of tested females
Age/years
0-5 IU/ml
6-9 IU/ml
≥ 10 IU/ml
Sub total%
15-1905596412.420-245928830239.925-296723925226.830-345514615614.235-392159626.140-44109100.545-4900110.1total1927801847100
![Page 27: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/27.jpg)
Age-Specific Fertility Rates and Total Fertility Rates by Region-1995 (PCBS)
Age GroupWest BankGaza StripTotal15-19100144114
20-24273340294
25-29264347291
30-34229289248
35-39155230177
40-446212382
45-49555
Total Fertility Rate (TFR)5.447.416.06
![Page 28: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/28.jpg)
Dose Rubella IgG levels change with age?
• Do we have deferent IgG levels with different women age groups?
![Page 29: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/29.jpg)
Rubella IgG IU levels with ageIU IgG LevelAge 15-29
YEARS%Age 30-49 YEARS%
0-1000646100%241100%
100-1000
19630.347531.12
50-9920231.277129.46
10-4920832.28033.2
0-9274.2135.4
![Page 30: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/30.jpg)
Back to the aim of our study
1) Finding out the % of rubella susceptible of age bearing women in Palestinian community.
The answer is 4.4 % according to our findings
![Page 31: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/31.jpg)
Back to the aim of our study cont.
•2 )Efficiency of vaccination program•According to our findings, the vaccine
outcome consists with the expected results proposed by the manufacturers .
![Page 32: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/32.jpg)
Back to the aim of our study cont.
•3 )Subsequently the need for including rubella test as a routine test for pregnant ladies in their first pregnancies.
•We believe it is worth thinking of including rubella IgG as regular test in pregnant ladies follow up.
![Page 33: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/33.jpg)
Conclusions and Recommendations
According to our results:-1)4.4 % of Palestinian age bearing women are
Rubella susceptible.2)The above figures consists with data from
international research findings as well as with the expected outcome from the vaccine.
![Page 34: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/34.jpg)
3) As the cost estimate of CRS is 200,000$ (USA figures) it might be recommended doing the rubella IgG test for all pregnant ladies in their first pregnancy and keeping the results in their files for following pregnancies.
4) It is rather better to conceder the lady as rubella susceptible when equivocal result is obtained.
![Page 35: An-Najah 2 nd Medical International Conference](https://reader036.vdocuments.us/reader036/viewer/2022062422/56814038550346895daba401/html5/thumbnails/35.jpg)
Thank you